At 82.6x trailing earnings, the stock screens optically expensive, but the compression to a 16.3 Forward P/E alongside a 0.6 forward PEG signals that the market expects a sharp earnings inflection and is not fully pricing in that growth. A $322M market cap with a Price/Sales of 3 and Price/Book of 2.8 suggests a business valued more on recovery potential than on current profitability. The Altman Z-Score of 2.3 places the company in a gray zone—neither distressed nor unquestionably safe—while a Piotroski F-Score of 7 indicates solid underlying financial improvement. This is a turnaround-growth hybrid where the multiple implies skepticism, but forward valuation suggests meaningful upside if execution materializes.